Secondary failure of platelet recovery after allogeneic hematopoietic stem cell transplantation in pediatric acquired aplastic anemia: Incidence, risk factors, and clinical outcomes
Clinical Hematology International · 30.09.2026 · 8 (3)
DOI: 10.46989/001c.171012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Hematology International, online erschienen am 30.09.2026. Verfasst von Yue Shang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Labo…. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Secondary failure of platelet recovery (SFPR) poses a significant risk for life-threatening complications following hematopoietic stem cell transplantation (HSCT). However, the incidence, clinical outcomes, and risk factors associated with SFPR in the context of allogeneic HSCT (allo-HSCT) for pediatric patients with acquired aplastic anemia (AA) remain unclear. We conducted a retrospective review of 86 consecutive acquired AA children who underwent allo-HSCT at our center from December 2017 to November 2023. The 1-year cumulative incidence of SFPR was found to be 11.6% (95% confidence interval [CI]: 6.2%-21.1%). The median time to SFPR was 2 months (range: 1-5 months) post-transplantation. To clarify the risk factors for SFPR, 9 SFPR cases and 69 non-SFPR cases were further analyzed. Multivariable analyses revealed that age, pre-transplantation body mass index (BMI) and a history of grade Ⅲ-Ⅳ acute graft-versus-host disease (aGVHD) were the most significant predictors for SFPR post-transplantation (p < 0.05). Additionally, we found that the 2-year overall survival rate was significantly lower in children with SFPR compared to those without (74.1% vs. 96.7%; p < 0.005). Ultimately, 4 patients achieved full platelet count recovery, with 2 patients becoming transfusion-independent. However, 1 patient still requires periodic platelet transfusions, and 2 patients unfortunately died.Among the 6 patients who received thrombopoietin receptor agonist therapy, an overall response rate of 66.6% was observed, suggesting the potential efficacy of this treatment approach in managing SFPR. This study underscores the need for vigilant monitoring of platelet recovery in pediatric HSCT recipients and highlights the need for further research into the etiology of SFPR to improve clinical outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatric Hematology, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hos…
- Tianjin Institute of Health Science, Tianjin 301600, China.
Zitieren
APA
Shang, Y., Ren, Y., Liu, L., Wang, X., Jiang, C., Chen, X., Wan, Y., Zhang, A., Zhang, X., Liu, F., Zhang, L., Chen, Y., Zou, Y., Chen, X., Yang, W., Zhu, X., & Guo, Y. (2026). Secondary failure of platelet recovery after allogeneic hematopoietic stem cell transplantation in pediatric acquired aplastic anemia: Incidence, risk factors, and clinical outcomes. Clinical Hematology International, 8(3). https://doi.org/10.46989/001c.171012
Vancouver
Shang Y, Ren Y, Liu L, Wang X, Jiang C, Chen X, et al. Secondary failure of platelet recovery after allogeneic hematopoietic stem cell transplantation in pediatric acquired aplastic anemia: Incidence, risk factors, and clinical outcomes. Clinical Hematology International. 2026;8(3). doi:10.46989/001c.171012
BibTeX
@article{Shang2026,
author = {Shang, Yue and Ren, Yuanyuan and Liu, Lipeng and Wang, Xin and Jiang, Chaoqian and Chen, Xia and Wan, Yang and Zhang, Aoli and Zhang, Xiaoyan and Liu, Fang and Zhang, Li and Chen, Yumei and Zou, Yao and Chen, Xiaojuan and Yang, Wenyu and Zhu, Xiaofan and Guo, Ye},
title = {Secondary failure of platelet recovery after allogeneic hematopoietic stem cell transplantation in pediatric acquired aplastic anemia: Incidence, risk factors, and clinical outcomes},
journal = {Clinical Hematology International},
year = {2026},
volume = {8},
number = {3},
doi = {10.46989/001c.171012}
}
EUVIMED